Jana Kristin Eckert

Jana Kristin Eckert

Auto-generated profile, based on publicly available information

Jana Kristin Eckert

Dr von Haunersches Kinderspital Kinderklinik und Kinderpoliklinik der Ludwig Maximilian Universitat Munchen

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2008 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
CPChrista Pfleiderer
Christa Pfleiderer
JBJohannes Blümel
Johannes Blümel
MSMichael Schmidt
Michael Schmidt
WRW. Kurth Roth
W. Kurth Roth
MHM. Kai Houfar
M. Kai Houfar
CNC. Micha Nübling
C. Micha Nübling

31 March 2024 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
ABAndreas Böck
Andreas Böck
KUKathrin Urner
Kathrin Urner
JEJana Kristin Eckert
Jana Kristin Eckert
MSMichael Salvermoser
Michael Salvermoser
KLKristina Laubhahn
Kristina Laubhahn
CGCHAMP study group; PASTURE study group
CHAMP study group; PASTURE study group
Background: Numerous children present with early wheeze symptoms, yet solely a subgroup develops childhood asthma. Early identification of children at risk is key for clinical monitoring, timely patient‐tailored treatment, and preventing chronic, severe sequelae. For early prediction of childhood asthma, we aimed to define an integrated risk score combining established risk factors with genome‐wide molecular markers at birth, complemented by subsequent clinical symptoms/diagnoses (wheezing, atopic dermatitis, food allergy).Methods: Three longitudinal birth cohorts (PAULINA/PAULCHEN, n = 190 + 93 = 283, PASTURE, n = 1133) were used to predict childhood asthma (age 5–11) including epidemiological characteristics and molecular markers: genotype, DNA methylation and mRNA expression (RNASeq/NanoString). Apparent (ap) and optimism‐corrected (oc) performance (AUC/R2) was assessed leveraging evidence from independent studies (Naïve‐Bayes approach) combined with high‐dimensional logistic regression models (LASSO).Results: Asthma prediction with epidemiological characteristics at birth (maternal asthma, sex, farm environment) yielded an ocAUC = 0.65. Inclusion of molecular markers as predictors resulted in an improvement in apparent prediction performance, however, for optimism‐corrected performance only a moderate increase was observed (upto ocAUC = 0.68). The greatest discriminate power was reached by adding the first symptoms/diagnosis (up to ocAUC = 0.76; increase of 0.08, p = .002). Longitudinal analysis of selected mRNA expression in PASTURE (cord blood, 1, 4.5, 6 years) showed that expression at age six had the strongest association with asthma and correlation of genes getting larger over time (r = .59, p < .001, 4.5–6 years).Conclusion: Applying epidemiological predictors alone showed moderate predictive abilities. Molecular markers from birth modestly improved prediction. Allergic symptoms/diagnoses enhanced the power of prediction, which is important for clinical practice and for the design of future studies with molecular markers.

1 December 2021 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
OKOliver Kumpf
Oliver Kumpf
KGKathleen Gürtler
Kathleen Gürtler
SSSaubashya Sur
Saubashya Sur
MPMonalisa Parvin
Monalisa Parvin
LZLena-Karoline Zerbe
Lena-Karoline Zerbe
RSRalf R. Schumann
Ralf R. Schumann
LPS binding protein (LBP) is an important innate sensor of microbial cell wall structures. Frequent functionally relevant mutations exist and have been linked to influence susceptibility to and course of bacterial infections. We examined functional properties of a single nucleotide polymorphism resulting in an exchange of phenylalanine to leucine at position 436 of LBP (rs2232618) and compared the frequent variant of the molecule with the rare one in ligand binding experiments. We then stimulated RAW cells with bacterial ligands in the presence of serum obtained from individuals with different LBP genotypes. We, furthermore, determined the potential effects of structural changes in the molecule by in silico modeling. Finally, we analyzed 363 surgical patients for this genetic variant and examined incidence and course of sepsis following surgery. We found that binding of LBP to bacterial ligands was reduced, and stimulation of RAW cells resulted in an increased release of TNF when adding serum from individuals carrying the F436L variant as compared with normal LBP. In silico analysis revealed structural changes of LBP, potentially explaining some of the effects observed for the LBP variant. Finally, patients carrying the F436L variant were found to be similarly susceptible for sepsis. However, we observed a more favorable course of severe infections in this cohort. Our findings reveal new insights into LPS recognition and the subsequent activation of the innate immune system brought about by LBP. The identification of a genetic variant of LBP influencing the course of sepsis may help to stratify individuals at risk and thus reduce clinical complications of patients.

16 August 2021 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
JEJana Kristin Eckert
Jana Kristin Eckert
JKJulia Kahle
Julia Kahle
ABAndreas Böck
Andreas Böck
KZKathrin Zeber
Kathrin Zeber
KUKathrin Urner
Kathrin Urner
FCfor the CHAMP Consortium
for the CHAMP Consortium

17 July 2026 in Allergy
Verified
Journal Article
Open access
PDF file
ZSZeyang Shen
Zeyang Shen
JEJana K. Eckert
Jana K. Eckert
RSRichard Saffery
Richard Saffery
KAKatrina J. Allen
Katrina J. Allen
AWAudrey Walsh
Audrey Walsh
PFPamela A Frischmeyer-Guerrerio
Pamela A Frischmeyer-Guerrerio
Background: Atopic dermatitis (AD), food sensitization (FS), and food allergy (FA) frequently co‐occur in infancy, but the factors underlying distinct atopic phenotypes remain unclear. Although FLG null mutations are major genetic risk factors for AD, they explain only part of disease heritability, suggesting a potential role for the skin microbiome. This study examined how early‐life skin microbiome composition and its interaction with host genetics contribute to distinct atopic phenotypes in infancy. Methods: We analyzed > 1000 skin swabs from 429 infants in the VITALITY cohort using deep shotgun metagenomic sequencing at 2–3 months (pre‐diagnosis) and 12 months (post‐diagnosis). Differential abundance, strain‐level, and microbial genome‐wide association analyses were performed to identify taxonomic and functional features associated with AD, FS, FA, their co‐occurrence, and FLG mutation status. Results: Within AD, microbial signatures differed by co‐occurring FA or FS. At 12 months, Staphylococcus epidermidis was enriched in infants with AD alone, whereas infants with AD and FA showed decreased Staphylococcus hominis and Lactococcus species, and increased Dermacoccus nishinomiyaensis and Malassezia slooffiae . At 2–3 months, early skin dysbiosis characterized by enrichment of Staphylococcus species was associated with later development of AD with FS or FA, but not AD alone. Among infants with AD, FLG mutation carriers showed additional microbial shifts, including reduced Streptococcus species and increased M. slooffiae . Strain‐level analyses revealed mother–infant sharing of AD‐associated taxa, and microbial genome‐wide association analyses identified species‐specific genes linked to AD severity. Conclusions: Infant atopic phenotypes are associated with distinct, phenotype‐specific skin microbiome features that emerge before and after disease onset, highlighting the microbiome as a potential target for early risk stratification.

5 January 2021
Verified
Preprint
Open access
PDF file
JEJana Eckert
Jana Eckert
JKJulia Kahle
Julia Kahle
ABAndreas Böck
Andreas Böck
KZKathrin Zeber
Kathrin Zeber
KUKathrin Urner
Kathrin Urner
BSBianca Prof. Dr. Schaub
Bianca Prof. Dr. Schaub
Background: Allergic diseases are the most prevalent chronic childhood diseases resulting in a massive societal and economic burden for the community and a significant reduction of health-related quality of life (HRQoL) for affected families. The project CHAMP (CHildhood Allergy and tolerance: bioMarkers and Predictors) was funded in 2017 by the German Federal Ministry for Education and Research. Methods: CHAMP investigates the determinants of different allergic diseases from birth to adolescence to identify clinically relevant biomarkers predicting onset, progression, remission and severity. Data on HRQoL and patient’s needs and requirements were collected, supported by the German Asthma and Allergy Association (DAAB). Using validated questionnaires and outpatient visits, eight subprojects analysed allergic diseases in epidemiological or clinical cohorts (more than 2500 children/adolescents), sampling numerous biomaterials to assess omics on several levels. Murine models disentangled underlying mechanisms of early tolerance, translating findings from the cohorts to models and vice versa. Results: The DAAB survey, including 851 participants, showed that 83% were interested in prediction of the course of different current allergic diseases and future manifestation. 86% of participants considered doctor’s specialized training and their education as highly important, over 70% chose research for allergy understanding and prevention as critical. CHAMP addresses these needs. Common SOPs have been established and recruitment is ongoing. Conclusion: The DAAB patient survey confirmed the critical need for translational allergy research. CHAMP envisions to predict onset, tolerance and remission of allergic diseases and to identify disease sub-phenotypes for future development of preventive strategies and novel avenues for therapeutic options.